10 results about "Ditazole" patented technology

The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

The application belongs to the field of organic photoelectric functional materials, and discloses an organic up-conversion red light photosensitizer material, a preparation method and application. The material has the structure shown in the following formula (I). The molecule has a D-pi-A-pi-D structure, wherein 4,7-dibromo benzo[1,2-c:4,5-c'] bis([1,2,5]thiadiazole), 4,7-dibromo benzo[c]-1,2,5-thiadiazole, 4,7-dibromo benzo[d]thiazole and 4,7-dibromo-2,1,3-benzoselenadiazole are used as strong electron acceptors, can reduce the energy gap of the molecule, and make the absorption peak / emission peak red shift; triphenylamine is used as a strong electron donor and a pi-bridge, a spiral structure is formed, steric hindrance is increased, and the aggregation-induced emission characteristics are ensured; the carboxyl group on the triphenylamine provides good amphiphilicity for the overall structure. The synthetic route of the application is simple, is a potential red light TADF material, and has good fluorescence quantum yield and up-conversion efficiency.

The present invention discloses two novel synthetic methods for preparing monothiol-labeled mesylphenyl oxadiazole active esters. These methods use inexpensive commercial raw materials to prepare two kinds of mesylphenyl oxadiazole active esters for thiol labeling of antibodies, polypeptides, hydrogels, etc. through conventional transformations such as condensation and coupling. The preparation method of the present invention has a simple process, easily available raw materials, high product added value, and has good economic benefits and market prospects.

This invention relates to a photosensitizer with a D1-π-A-π-D2 type structure based on asymmetric end-capped donor units. This material is characterized by using 4-(5-(4-(9H-carbazole-9-yl)phenyl)) as donor units (D1) and 5-(4-(diphenylamino)phenyl) as donor units (D2), with isooctylthiophene as the connecting π-bridge, and phenazine as the central acceptor unit (A), specifically naphthiazo[1,2-b][1,2,5]thiadiazo[3,4-g]quinoxaline and [1,2,5]thiadiazo[3,4-i]dithienozo[2,3-a:3',2'-c]phenazine. The photophysical properties of this D1-π-A-π-D2 type photosensitizer were tested, and a novel photosensitizer with high photothermal conversion efficiency and high reactive oxygen species (ROS) yield was developed. The material involved in this invention has near-infrared II region imaging and photothermal in-situ imaging diagnostic functions, and is expected to be used as an organic photosensitizer material for integrated photothermal and photodynamic diagnosis and treatment.

The invention relates to compounds of Formula (I) as described herein, useful as histone deacetylase 6 (HDAC6) inhibitors. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in therapy.

This invention discloses two novel methods for synthesizing dithiol-bridged labeled bis(methylsulfonyl)phenyloxadiazole. These methods utilize inexpensive, commercially available raw materials and conventional transformations such as condensation and coupling to prepare two bis(methylsulfonyl)phenyloxadiazoles suitable for dithiol-bridged labeling of antibodies, peptides, and hydrogels. The preparation methods of this invention are simple, use readily available raw materials, and produce high-value-added products, demonstrating significant economic benefits and market potential.

The present invention provides modified catalytic antibody 38C2 with arylation of the reactive lysine residue (Lys99). The Lys99 residue is arylated with a heteroaryl methyl sulfonyl compound such as methylsulfone phenyl oxadiazole (MS-PODA). The invention also provides antibody conjugated agents (e.g., antibody drug conjugates) that contain an agent moiety that is site-specifically conjugated to 38C2 via a methyl sulfonyl compound. Further provided in the invention are methods of making the antibody conjugated agents and therapeutic applications of the antibody conjugated agents.

The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondriatargeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and / or solvate thereof.